Immunovant (IMVT) vs Kodiak Sciences (KOD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kodiak Sciences (KOD) has outperformed Immunovant (IMVT) over the past year, gaining 540.1% versus a gain of 98.9%. Over five years, IMVT leads with a +267.4% price change compared with -18.7% for KOD. Immunovant is the larger company by market cap ($6.62 billion vs $5.72 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMVT | KOD |
|---|---|---|
| Share price | $32.04 | $91.08 |
| Market cap | $6.62B | $5.72B |
| 1-day change | -0.22% | -1.36% |
| YTD return | +26.04% | +225.75% |
| 1-year return | +98.88% | +540.06% |
| 5-year return | +267.43% | -18.66% |
| EPS (TTM) | $-2.81 | $-4.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-505.61M | $-229.97M |
| 52-week high | $45.42 | $104.00 |
| 52-week low | $16.08 | $10.94 |
| Distance from 52-week high | -29.46% | -12.42% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +52.56% | +28.10% |
| Average volume | 1.23M | 1.57M |
| Shares outstanding | 206.55M | 62.85M |
| Employees | 315 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KOD has outperformed IMVT by 441.2 percentage points over the past year.
About Immunovant
IMVT stock →Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees
About Kodiak Sciences
KOD stock →Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
IMVT vs KOD FAQ
Which is bigger, Immunovant or Kodiak Sciences?
Immunovant (IMVT) is larger, with a market capitalization of $6.62B compared with $5.72B for Kodiak Sciences (KOD).
Which stock has performed better over the past year, IMVT or KOD?
KOD returned +540.06% over the past 12 months, compared with +98.88% for IMVT (price return, excluding dividends). Past performance does not predict future results.
Are Immunovant and Kodiak Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.